Clinical trial
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the…
NCT00031083 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00031083 |
|---|---|
| Title | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas |
| Official title | A Multi-center, Open Label, Two Part, Dose Escalation Study to Determine the Tolerability of Interferon-Beta Gene Transfer (BG00001) in the Treatment of Recurrent or Progressive Grade III and Grade IV Gliomas |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma |
| Intervention type | Genetic |
| Interventions | Interferon-beta |
| Enrollment | 12 |
| Start date | Apr 2, 2002 |
| Completion | Oct 10, 2003 |
| First posted | Feb 22, 2002 |
| Last update posted | Nov 17, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: